Parkinson's drug WD-1603: does timing matter?

NCT ID NCT07442591

Recruiting now Knowledge-focused Sponsor: Shanghai WD Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing how the body handles WD-1603, a combination of carbidopa and levodopa used for Parkinson's disease, when taken at different time intervals. Twelve healthy adults will take the drug twice a day on three separate days, with gaps of 5, 6, or 7 hours between doses. Researchers will measure drug levels in the blood and check for side effects to find the best dosing schedule.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carbidopa and levodopa controlled-release tablets
What this could lead to: If successful, this study could help determine the best dosing schedule for WD-1603, potentially improving treatment for Parkinson's disease.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. Results may not predict effects in people with Parkinson's, and the drug may still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALHTY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALHTY

Contacts and locations

Locations

Shanghai Xuhui Central Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.